Cipla gains on plan to invest up to 100 million pounds in UK subsidiary

07 Jul 2014 Evaluate

Cipla is currently trading at Rs. 450.00, up by 2.10 points or 0.47% from its previous closing of Rs. 447.90 on the BSE.

The scrip opened at Rs. 450.00 and has touched a high and low of Rs. 453.00 and Rs. 448.55 respectively. So far 22340 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 453.00 on 07-Jul-2014 and a 52 week low of Rs. 366.70 on 24-Feb-2014.

Last one week high and low of the scrip stood at Rs. 453.00 and Rs. 435.20 respectively. The current market cap of the company is Rs. 35962.85 crore.

The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.75% and 27.35% respectively.

Cipla, in collaboration with the UK government, has expressed its intention to make investments of up to 100 million pounds in its UK subsidiary over the next few years. The investments are expected to facilitate the launch of a range of products in the area of respiratory, oncology and antiretroviral medicines to further Cipla’s higher purpose of universal affordable access.

The company also plans to invest in R&D activities, clinical trials and expand further internationally. The investment underscores the growing importance of UK in the company’s long term strategy.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries.

 

Cipla Share Price

1504.80 -0.25 (-0.02%)
29-Dec-2025 10:06 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.10
Dr. Reddys Lab 1267.00
Cipla 1504.80
Zydus Lifesciences 907.90
Lupin 2101.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×